Victory Capital Management Inc. Sells 31,839 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Victory Capital Management Inc. reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 42.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,049 shares of the medical instruments supplier’s stock after selling 31,839 shares during the period. Victory Capital Management Inc. owned 0.19% of LeMaitre Vascular worth $3,542,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Shaker Investments LLC OH boosted its position in shares of LeMaitre Vascular by 1.3% in the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 169 shares during the last quarter. GAMMA Investing LLC lifted its holdings in LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares in the last quarter. nVerses Capital LLC lifted its holdings in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares in the last quarter. Albion Financial Group UT lifted its holdings in LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after acquiring an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp lifted its holdings in LeMaitre Vascular by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after acquiring an additional 225 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders sold 43,251 shares of company stock worth $3,714,994 over the last three months. Insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Barrington Research lifted their price target on LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. JMP Securities lifted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research report on Friday, May 31st. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $94.40.

LeMaitre Vascular Stock Up 0.3 %

Shares of NASDAQ:LMAT opened at $90.00 on Tuesday. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $92.90. The stock has a market cap of $2.02 billion, a PE ratio of 59.60, a P/E/G ratio of 2.28 and a beta of 0.88. The business has a 50 day moving average of $86.44 and a 200-day moving average of $77.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.37 earnings per share. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s payout ratio is presently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.